Categories

Meta

Recent Posts

Intercell and Romark declare IC41-nitazoxanide syndicate clinical trials on account of HCV

Posted in Disease, Infection on October 20th, 2010

Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to inaugurate clinical trials of Intercell’s investigational healthy Hepatitis C virus (HCV) vaccine, IC41, in suspension with Romark’s antiviral medicament, nitazoxanide, during the before all half of 2011.

Intercell’s vaccine possibility has demonstrated a ceaseless reduction of viral worry in long-lasting Hepatitis C (CHC) patients in a Viewpoint Read the rest of this entry »

Stylish materials from ESHO/EORTC STBSG Form III clinical cramming of hyperthermia

Posted in Medical Condition on October 20th, 2010

BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced flier in Internal Medicament Scuttlebutt Digital Network of latest figures from the ESHO/EORTC Flexile Series and Bone Sarcoma Bring (STBSG) Incorporate ease out III clinical survey of hyperthermia. (Freeman, S. [10/5/2010]. Regional Hyperthermia Chemo Helps High-Risk, Nonextremity, Relieve Pile Sarcomas. Internal Pharmaceutical Expos Digital Network. Read the rest of this entry »

Cytheris initiates ORVACS Taper off II clinical conditional to bone up on HIV infection

Posted in Disease, Infection on October 19th, 2010

Cytheris SA, a clinical lap biopharmaceutical comrades focused on inquiry and condition of revitalized therapies due to the fact that vaccinated modulation, today announced the origination of Time II clinical burr under the saddle of the company’s investigative immunomodulatory factor, CYT107 (rhIL-7), in federation with two telling antiretroviral drugs represented above all the integrase inhibitor raltegravir (ISENTRESS® – Merck & Co.) and Read the rest of this entry »

U.S. Community Court issues finding in NPWT unequivocal action

Posted in Medical Patent on October 18th, 2010

The U.S. Partition Court with a view the Western Partition of Texas has issued a resolution in the flagrant suit between Kinetic Concepts, Inc. (NYSE:KCI), Wake Forest University and Smith & Nephew, Inc. The Court held that the clear claims licensed generally KCI from Wake Forest University and asserted in this case are incorrect. KCI desire resume to analyze the Court’s ruling and assess its next steps including, quantity other options, a insist Read the rest of this entry »

Archimedes publishes results from FPNS Status III clinical ruminate on as far as something breakthrough cancer dolour

Posted in Drug Trial on October 14th, 2010

Archimedes Pharma, an emerging specialty pharma retinue focused on oncology, trouble, neurology and deprecating nurse sectors, today announced declaration of results from a Remove III, long-term refuge, tolerability and consistency of make, clinical investigation of fentanyl pectin nasal distribute (FPNS) in the treatment of breakthrough cancer torment (BTCP).

The article, entitled "Long-term refuge, tolerability, and consistency Read the rest of this entry »

Kennedy Krieger Pioneer launches end II clinical endeavour to analyse Revatio owing DMD treatment

Posted in Drug Trial on October 14th, 2010

Kennedy Krieger Organize announced today the inauguration of a first‐of‐its‐kind, include II clinical pain in the arse to examine a treatment in spite of verve malady in individuals with Duchenne sturdy dystrophy (DMD). Made plausible via a $545,000 bequest from Cicerone Trials With it, an innovative DMD pep organized and managed alongside Charley’s Wherewithal Inc. and The Nash Avery Fundamental principle, with additional subsistence from Read the rest of this entry »

Magellan clinical leaders to chat about solutions to develop mind-set illnesses

Posted in Medical Condition on October 14th, 2010

On the heels of Certifiable Affliction Awareness Week, clinical leaders from Magellan Constitution Services, Inc., (NASDAQ:MGLN) an earnestness principal in behavioral trim trouble handling, are promptly turnout to deliberate over a diversity of innovative solutions exchange for addressing the atypical needs and improving outcomes of individuals with temperament illnesses. Expanse the items on the agenda is a groundbreaking clinical leadership Read the rest of this entry »

JAMA publishes Probuphine Discontinue 3 clinical annoyance facts

Posted in Drug Trial on October 13th, 2010

Titan Pharmaceuticals, Inc. (OTC Account Surface: TTNP) today announced that details from its time past completed and announced Wind up 3 randomized, placebo-controlled clinical adversity of Probuphine were published in the Minutes of the American Medical Federation (JAMA).  The article highlights figures from the 163-patient tribulation, which showed that patients receiving Titan’s Probuphine root had significantly less prohibit opioid run Read the rest of this entry »

Brink announces TH-302 Facet 1/2 clinical stab interim results

Posted in Drug Trial on October 13th, 2010

Outset Pharmaceuticals, Inc. (Nasdaq:THLD) today announced interim results from an running Usher in 1/2 clinical distress in diversified true tumors interrelated to its hypoxia-activated prodrug, TH-302. The results were presented at the European Institute allowing for regarding Medical Oncology (ESMO) Annual Confluence being held in Milan, Italy.

Today’s display focused on possibly man clinical enquiry, the 402 burr under the saddle. Read the rest of this entry »

Ocular Therapeutix completes Ammunition of By-law clinical reading with moxifloxacin punctum cork

Posted in Drug Trial on October 13th, 2010

Ocular Therapeutix, Inc. announced today the finishing-off of a top Standard of Regulation clinical lucubrate with their best-seller continued treat parturition moxifloxacin punctum promotion.

The ponder was a single-site, single-armed, single-dose work in which ten patients received the punctum block the moment that following cataract surgery and were evaluated throughout a 10-day time. Select upshot measures were advert retention and Read the rest of this entry »